Table 3.
Summary of treatment response in Japanese patients from the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 studies
| n (%) | KEYNOTE-059 | KEYNOTE-059 | KEYNOTE-061 | KEYNOTE-061 | KEYNOTE-062 | KEYNOTE-062 | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| All patients | CPS ≥ 1 | CPS ≥ 1 | CPS ≥ 10 | CPS ≥ 1 | CPS ≥ 10 | |||||
| Pembrolizumab | Pembrolizumab | Pembrolizumab | Chemotherapy | Pembrolizumab | Chemotherapy | Pembrolizumab | Chemotherapy | Pembrolizumab | Chemotherapy | |
| n = 34 | n = 13 | n = 27 | n = 38 | n = 12 | n = 7 | n = 38 | n = 32 | n = 16 | n = 14 | |
| ORR | 3 (9) | 2 (15) | 2 (7) | 7 (18) | 0 | 1 (14) | 11 (29) | 11 (34) | 5 (31) | 4 (29) |
| CR | 2 (6) | 1 (8) | 0 | 1 (3) | 0 | 0 | 3 (8) | 2 (6) | 2 (13) | 0 |
| PR | 1 (3) | 1 (8) | 2 (7) | 6 (16) | 0 | 1 (14) | 8 (21) | 9 (28) | 3 (19) | 4 (29) |
| SD | 6 (18) | 1 (8) | 10 (37) | 16 (42) | 5 (42) | 4 (57) | 9 (24) | 13 (41) | 5 (31) | 7 (50) |
| PD | 23 (68) | 10 (77) | 14 (52) | 12 (32) | 7 (58) | 2 (29) | 4 (11) | 2 (6) | 3 (19) | 1 (7) |
| Not availablea | 2 (6) | 0 | 1 (4) | 3 (8) | 0 | 0 | 5 (13) | 4 (13) | 3 (19) | 2 (14) |
CPS combined positive score, CR complete response, ORR objective response rate, PD progressive disease, PR partial response, SD stable disease
aNot available includes patients who were not evaluable and patients with no postbaseline assessment as of the data cutoff date